UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): December 12, 2009
BIONEUTRAL
GROUP, INC.
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
333-149235
|
26-0745273
|
(State
or Other Jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
of
Incorporation)
|
Identification
No.)
|
211
Warren Street
|
|
Newark,
New Jersey
|
07103
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (973) 286-2899
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item
1.02 Termination
of a Material Definitive Agreement
Item
5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
James Crane submitted his decision to
resign as the Company's Chief Financial Officer on December 12, 2009. As a result of such
resignation, the Company's relationship with Mr. Crane pursuant to the certain
Consulting Agreement, dated as of May 20, 2009, between the Company and James
Crane, was terminated effective January 12, 2009.
Item
8.01 Other
Events.
The Company retained Barry M. Shereck
in December 2009 as a consultant to assist the Company with respect to certain
accounting matters until such time as it appoints a Chief Financial
Officer. Mr. Shereck is a certified public accountant and within the
last five years was the chief financial officer of a public company in the
United States and a public company in Europe.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
BIONEUTRAL GROUP, INC.
|
||
By:
|
/s/
Stephen J. Browand
|
|
Name:
Stephen J. Browand
|
||
Title:
President and Chief Executive
Officer
|
Dated: February
1, 2010